Abrocitinib bests placebo for treatment of atopic dermatitis
25 March 2021

The corresponding proportions of patients in each group with an Eczema Area and Severity Index-75 response at week 12 were 70.3, 58.7, 58.1, and 27.1 percent. With respect to itch response at week 2, the 200-mg dose, but not the 100-mg dose, of abrocitinib was superior to dupilumab. With respect to most other key secondary end-point comparisons at week 16, neither abrocitinib dose differed significantly from dupilumab.

"Longer and larger trials are necessary to determine the efficacy and safety of abrocitinib and to compare it with other JAK inhibitors and with biologic agents used for the treatment of atopic dermatitis," the authors write.

The study was funded by Pfizer, the developer of abrocitinib.

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved.